Close Menu

NEW YORK – Adaptive Biotechnologies and lab services provider Q2 Solutions said on Monday that they will partner to market Adaptive's ImmunoSeq assay.

Under the terms of the agreement, Q2 Solutions will offer its customers ImmunoSeq, a next-generation sequencing-based assay that analyzes immune cell receptors, as well as ImmunoSeq T-Map COVID, a research product and data analysis service that can assess T cell response to COVID-19 vaccines in development and track the persistence of the immune response over time.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.